[
  {
    "ts": null,
    "headline": "Expedia price target raised to $185 from $180 at Morgan Stanley",
    "summary": "Morgan Stanley analyst Brian Nowak raised the firm’s price target on Expedia (EXPE) to $185 from $180 and keeps an Equal Weight rating on the shares. The firm sees GPU enabled and GenAI tool adoption driving fundamental upside and outperformance among the North American Internet group. Among the group, the firm identifies Amazon (AMZN) as its new “Top Pick” as it sees GPU-related investments widening its retail advantage to “take more share, more profitably,” while it calls Meta (META) a “GenAI",
    "url": "https://finnhub.io/api/news?id=57ee74cdd8309c3f72553c72421dd37ca85c84bbf6682e4851cfbfe57f3355e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736864525,
      "headline": "Expedia price target raised to $185 from $180 at Morgan Stanley",
      "id": 132481167,
      "image": "https://media.zenfs.com/en/tipranks_452/3d857af77a14081b57c6cc8755970adf",
      "related": "EXPE",
      "source": "Yahoo",
      "summary": "Morgan Stanley analyst Brian Nowak raised the firm’s price target on Expedia (EXPE) to $185 from $180 and keeps an Equal Weight rating on the shares. The firm sees GPU enabled and GenAI tool adoption driving fundamental upside and outperformance among the North American Internet group. Among the group, the firm identifies Amazon (AMZN) as its new “Top Pick” as it sees GPU-related investments widening its retail advantage to “take more share, more profitably,” while it calls Meta (META) a “GenAI",
      "url": "https://finnhub.io/api/news?id=57ee74cdd8309c3f72553c72421dd37ca85c84bbf6682e4851cfbfe57f3355e7"
    }
  },
  {
    "ts": null,
    "headline": "Expedia: Expect Margin Expansion From Strict Cost Discipline And Optimization Efforts",
    "summary": "EXPE presents a compelling investment opportunity for investors who are looking to gain exposure in the global travel industry. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=24c99d6da6e118a6475d9f92eb8f1e8c4e75c575a05e38dc2bd5d759711cb456",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736837685,
      "headline": "Expedia: Expect Margin Expansion From Strict Cost Discipline And Optimization Efforts",
      "id": 132393106,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518757834/image_518757834.jpg?io=getty-c-w1536",
      "related": "EXPE",
      "source": "SeekingAlpha",
      "summary": "EXPE presents a compelling investment opportunity for investors who are looking to gain exposure in the global travel industry. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=24c99d6da6e118a6475d9f92eb8f1e8c4e75c575a05e38dc2bd5d759711cb456"
    }
  },
  {
    "ts": null,
    "headline": "Patient Capital Management Q4 2024 Investment Review",
    "summary": "During the fourth quarter of 2024, the Patient Opportunity Equity Strategy generated a total return of 8.2% net of fees. Read more here.",
    "url": "https://finnhub.io/api/news?id=4c46c494af86e68782518c362fabf40854d5bfb319dcb8fb785b81e230f6b6f1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736829600,
      "headline": "Patient Capital Management Q4 2024 Investment Review",
      "id": 132392476,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1089222846/image_1089222846.jpg?io=getty-c-w1536",
      "related": "EXPE",
      "source": "SeekingAlpha",
      "summary": "During the fourth quarter of 2024, the Patient Opportunity Equity Strategy generated a total return of 8.2% net of fees. Read more here.",
      "url": "https://finnhub.io/api/news?id=4c46c494af86e68782518c362fabf40854d5bfb319dcb8fb785b81e230f6b6f1"
    }
  },
  {
    "ts": null,
    "headline": "Patient Capital Management Q4 2024 Commentary",
    "summary": "Patient Capital Management's Opportunity Equity Strategy surpassed the market to end up 26.5%, 150bps ahead of the S&P 500âs 25.0%. Click here to read the full fund letter.",
    "url": "https://finnhub.io/api/news?id=c91a9f164536b2ce0ecd620d1784405dbcd0ebf51731ed1a3244af49ec114ad7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736826000,
      "headline": "Patient Capital Management Q4 2024 Commentary",
      "id": 132392179,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972341389/image_1972341389.jpg?io=getty-c-w1536",
      "related": "EXPE",
      "source": "SeekingAlpha",
      "summary": "Patient Capital Management's Opportunity Equity Strategy surpassed the market to end up 26.5%, 150bps ahead of the S&P 500âs 25.0%. Click here to read the full fund letter.",
      "url": "https://finnhub.io/api/news?id=c91a9f164536b2ce0ecd620d1784405dbcd0ebf51731ed1a3244af49ec114ad7"
    }
  }
]